I didn't know you were in Vietnam. I am back in the U.S now.

I'm going down with the ship. Morrison can't get the merger to happen and just let the ship sink.

HUGE MERGER! https://www.theglobeandmail.com/investing/markets/markets-news/ACCESS%20Newswire/32470159/affluence-corporation-completes-acquisition-of-mingothings-slu/

HUGE MERGER! https://www.theglobeandmail.com/investing/markets/markets-news/ACCESS%20Newswire/32470159/affluence-corporation-completes-acquisition-of-mingothings-slu/

Good morning, all! Thanks, bro. This is a HUGE merger. I'm retired now and have been traveling the world. I still hold all my shares and even doubled down at 0.0003. I don't post much anymore, but I do check in from time to time to read and enjoy all the messages you and everyone else share here. Appreciate everyone's input!

MythicGoblin97 Thank you. This could potentially lead to a class action lawsuit, and I’d like to join the group if one is formed.

So, what is the current status of this lawsuit?

LOVED .21 per share. That is AWESOME!
YUP has to void the Preferred.

I knew something was off! So, it's a crime! They can't issue shares beyond the authorized limit—this is definitely getting interesting. I’m not selling at this price. If they cancel the 6.5 billion shares issued beyond the authorized limit, the value should be much higher than $0.0037.

I'm still holding as well. Yes, waiting is suck. The sad part is Morrison is clueless about the structure of the merger, and his advisor is also an idiot. Evobio products are incredible. All we need is a green light to launch the products.

I am now retired and travel a lot. Yes, UNQL is a mess this isn't the merger it's the buyout that works best for Ray scumbag.
Now Ray wanted to cash out an aggregate of 4,693,413,109 shares of Common Stock equal to $17,365,628. That is a sweet deal for him and the noteholders.

Legal Issues: If the company has issued Series B Preferred Stock and now wants to convert those shares into common stock, and this results in an excessive number of common shares being issued, there are a few possible legal concerns:

Exceeding the A/S: If the conversion of Series B Preferred Stock pushes the total number of outstanding common shares above the limit of the authorized shares, the company could face legal challenges unless they increase the A/S. In many jurisdictions, failing to properly authorize additional shares can result in claims of shareholder dilution or breaches of corporate governance rules.

Shareholder Approval: If the conversion mechanism was not clearly approved by shareholders or outlined in the terms of the preferred stock, insiders converting their shares in a way that significantly impacts other shareholders could result in claims of unfair conduct or potential shareholder lawsuits.

Fiduciary Duty: Company executives and insiders generally have a fiduciary duty to act in the best interests of the shareholders. If insiders are converting preferred stock to common stock in a way that results in an unfair of existing shareholders, it could potentially be challenged in court as a breach of fiduciary duty.

This is pathetic they rape the common shareholder. The a/s is only 800 m. They created the series of Preferred Stock and (B) gave it to themselves, but they now want the dividend based on the series B stock. Converting Series B Preferred Stock into common stock without increasing the authorized share count (A/S) or proper shareholder approval could violate the company's corporate charter and face legal challenges.

For the Three Months Ended November 30, 2024, total revenues were 112,226,717 which is very good. Compared to last year's revenue of 61,842,253.

Yes, the 10-Q was out on 03-07-2025. I'm not sure why OTC status still shows a grace period. Maybe they will update by next week.

$CTOR stock remains relatively unknown and under the radar. The company went public through its Initial Public Offering (IPO) on April 22, 2021. They own Lymphir, a Phase 3 FDA-approved drug with a unique mechanism of action that targets and reduces T-regulatory cells in the cancer microenvironment. It is currently being evaluated in combination with Keytruda, a PD-1 inhibitor, for the treatment of patients with recurrent solid tumors.
https://www.contractpharma.com/breaking-news/citius-lymphir-shows-potential-to-boost-pembrolizumab-efficacy/

Merck & Co., Inc. (MRK) sold under the brand name KEYTRUDA®, is the leading PD-1 inhibitor and the world's most prescribed drug, generating $25 billion in sales in 2023. The cost for Keytruda (25 mg/mL) intravenous solution is around $6,098 for a supply of 4 milliliters, depending on the pharmacy you visit. Keytrda by Merch is considered a game changer. Lymphir is the only drug out there that is comparable with Keytruda. In my opinion, this drug has the potential to capture a significant market once it becomes available.

Lymphir is the only CTCL therapy that targets the interleukin-2 (IL-2) receptor found on malignant T-cells and Tregs. This is the first indication for Lymphir and Citius Pharma’s first FDA-approved product.

Citius Pharmaceuticals (CTXR), the parent company, owns 92% of the outstanding shares of CTOR, and it also owns Mino-Lok.

Mino-Lok (For Cancer and Infection Prevention)
Successful Phase 3 Clinical Trial of Mino-Lok®. Mino-Lok® is on a pathway to a New Drug Application (NDA) submission

The FDA recently accepted the BLA for Lymphir as a treatment for patients with relapsed/refractory CTCL after at least one prior systemic therapy.
https://www.pharmexec.com/view/citius-pharmaceuticals-co-founder-ceo-discusses-recently-accepted-biologics-license-application-lymphir-for-the-treatment-relapsed-refractory-ctcl

(LYMPHIR) is gearing up to launch sales in the second quarter—exciting developments ahead! This stock is primed for significant growth and is currently an incredible bargain, greatly undervalued. With no upcoming offerings or dilution, and just a 5.9 million share float, the potential for a major move is clear. The chart is signaling a breakout toward $2.00, and it looks like this one is set to take off. It’s only a matter of time!

$CTOR News today stated they are evaluating strategic alternatives aimed at maximizing shareholder value through potential partnerships, joint ventures, mergers, acquisitions, and licensing.

I trade it! I didn't hold over the weekend.

We will have our days; it's only a matter of time.

Outstanding input! Thank you.

$BOXL monster move $$$

$POAI she blows $$$

$CTOR BULLISH ✨💎✨💎✨💎✨ Tomorrow breakout $2.00

(LYMPHIR) is set to begin selling this quarter – exciting times ahead! It's hard to believe that a Phase 3 FDA-approved stock with a market cap of only a few million dollars even exists. This situation is almost unbelievable.

This stock is set for a massive move. It's the best bargain and super undervalued. There is no offering, no dilute, and a 5.9 million share float. The chart looks poised for a breakout $2.00. This will fly soon! It’s a matter of time, Bullish.

Lymphir is the only CTCL therapy that targets the interleukin-2 (IL-2) receptor found on malignant T-cells and Tregs. This is the first indication for Lymphir and Citius Pharma’s first FDA-approved product.

Citius Pharmaceuticals (CTXR), the parent company, owns 92% of the outstanding shares of CTOR, and it also owns Mino-Lok.

Mino-Lok (For Cancer and Infection Prevention)
Successful Phase 3 Clinical Trial of Mino-Lok®. Mino-Lok® is on a pathway to a New Drug Application (NDA) submission

$CTOR BULLISH ✨💎✨💎✨💎Tomorrow breakout $2.00

(LYMPHIR) is set to begin selling this quarter – exciting times ahead! It's hard to believe that a Phase 3 FDA-approved stock with a market cap of only a few million dollars even exists. This situation is almost unbelievable.

This stock is set for a massive move. It's the best bargain and super undervalued. There is no offering, no dilute, and a 5.9 million share float. The chart looks poised for a breakout $2.00. This will fly soon! It’s a matter of time, Bullish.

Lymphir is the only CTCL therapy that targets the interleukin-2 (IL-2) receptor found on malignant T-cells and Tregs. This is the first indication for Lymphir and Citius Pharma’s first FDA-approved product.

Citius Pharmaceuticals (CTXR), the parent company, owns 92% of the outstanding shares of CTOR, and it also owns Mino-Lok.

Mino-Lok (For Cancer and Infection Prevention)
Successful Phase 3 Clinical Trial of Mino-Lok®. Mino-Lok® is on a pathway to a New Drug Application (NDA) submission

$CTOR BULLISH ✨💎✨💎✨💎✨ Tomorrow breakout $2.00

(LYMPHIR) is set to begin selling this quarter – exciting times ahead! It's hard to believe that a Phase 3 FDA-approved stock with a market cap of only a few million dollars even exists. This situation is almost unbelievable.

This stock is set for a massive move. It's the best bargain and super undervalued. There is no offering, no dilute, and a 5.9 million share float. The chart looks poised for a breakout $2.00. This will fly soon! It’s a matter of time, Bullish.

Lymphir is the only CTCL therapy that targets the interleukin-2 (IL-2) receptor found on malignant T-cells and Tregs. This is the first indication for Lymphir and Citius Pharma’s first FDA-approved product.

Citius Pharmaceuticals (CTXR), the parent company, owns 92% of the outstanding shares of CTOR, and it also owns Mino-Lok.

Mino-Lok (For Cancer and Infection Prevention)
Successful Phase 3 Clinical Trial of Mino-Lok®. Mino-Lok® is on a pathway to a New Drug Application (NDA) submission

$CTOR BULLISH ✨💎✨💎✨💎✨ Tomorrow breakout $2.00

(LYMPHIR) is set to begin selling this quarter – exciting times ahead! It's hard to believe that a Phase 3 FDA-approved stock with a market cap of only a few million dollars even exists. This situation is almost unbelievable.

This stock is set for a massive move. It's the best bargain and super undervalued. There is no offering, no dilute, and a 5.9 million share float. The chart looks poised for a breakout $2.00. This will fly soon! It’s a matter of time, Bullish.

Lymphir is the only CTCL therapy that targets the interleukin-2 (IL-2) receptor found on malignant T-cells and Tregs. This is the first indication for Lymphir and Citius Pharma’s first FDA-approved product.

Citius Pharmaceuticals (CTXR), the parent company, owns 92% of the outstanding shares of CTOR, and it also owns Mino-Lok.

Mino-Lok (For Cancer and Infection Prevention)
Successful Phase 3 Clinical Trial of Mino-Lok®. Mino-Lok® is on a pathway to a New Drug Application (NDA) submission

$CTOR +16.92 pm. Looking good!

$CTOR +16.92 pm. Looking good!

$CTOR +16.92 pm. Looking good!

$CTOR +8.75% she's ready to blow $$$...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175616047

$CTOR +8.75% she's ready to blow $$$...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175616047

$CTOR +8.75% she's ready to blow $$$...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175616047

I don't know why OTCM shows the wrong o/s it's my mistake not to dig into the DD

Thank you I will correct it. The float is still very small because the parent owns 92% o/s

This is why they need to fire James he’s just milking the stock. It’s frustrating because the company has so much potential, especially with OneMind Technologies.

I purchased stock yesterday following the $6.6B news. My first target is $30, then $45. If they secure the funding, it's full speed ahead to potential gains! $$$

$CTOR (LYMPHIR) is set to begin selling this quarter – exciting times ahead! It's hard to believe that a Phase 3 FDA-approved stock with a market cap of only a few million dollars even exists. This situation is almost unbelievable.

Market Cap 2,708,536 is incredibly low. This stock is set for a massive move. It's the best bargain, and super undervalued. No offering, no dilute. Outstanding Shares 2,355,249. The chart looks poised for the run. This will fly soon! It’s a matter of time Bullish.

Lymphir is the only CTCL therapy that targets the interleukin-2 (IL-2) receptor found on malignant T-cells and Tregs. This is the first indication for Lymphir and Citius Pharma’s first FDA-approved product.

Citius Pharmaceuticals (CTXR), the parent company, owns 92% of the outstanding shares of CTOR, and it also owns Mino-Lok.

Mino-Lok (For Cancer and Infection Prevention)
Successful Phase 3 Clinical Trial of Mino-Lok®. Mino-Lok® is on a pathway to a New Drug Application (NDA) submission which includes all the clinical trial data, manufacturing details, labeling information, and proposed use for the drug.

Phase 2 clinical trials. 1. CanStem 303C (Stem Cell Therapy for Cancer)
CanStem 303C is one of Citius Oncology's lead candidates. It's an investigational cell therapy aimed at treating cancer relapse and recurrence.

$CTOR (LYMPHIR) is set to begin selling this quarter – exciting times ahead! It's hard to believe that a Phase 3 FDA-approved stock with a market cap of only a few million dollars even exists. This situation is almost unbelievable.

Market Cap 2,708,536 is incredibly low. This stock is set for a massive move. It's the best bargain, and super undervalued. No offering, no dilute. Outstanding Shares 2,355,249. The chart looks poised for the run. This will fly soon! It’s a matter of time Bullish.

Lymphir is the only CTCL therapy that targets the interleukin-2 (IL-2) receptor found on malignant T-cells and Tregs. This is the first indication for Lymphir and Citius Pharma’s first FDA-approved product.

Citius Pharmaceuticals (CTXR), the parent company, owns 92% of the outstanding shares of CTOR, and it also owns Mino-Lok.

Mino-Lok (For Cancer and Infection Prevention)
Successful Phase 3 Clinical Trial of Mino-Lok®. Mino-Lok® is on a pathway to a New Drug Application (NDA) submission which includes all the clinical trial data, manufacturing details, labeling information, and proposed use for the drug.

Phase 2 clinical trials. 1. CanStem 303C (Stem Cell Therapy for Cancer)
CanStem 303C is one of Citius Oncology's lead candidates. It's an investigational cell therapy aimed at treating cancer relapse and recurrence.

$BLRX hod $0.31 ✨💎✨💎✨💎✨💎✨💎

$CTOR (LYMPHIR) is set to begin selling this quarter – exciting times ahead! It's hard to believe that a Phase 3 FDA-approved stock with a market cap of only a few million dollars even exists. This situation is almost unbelievable.

Market Cap 2,708,536 is incredibly low. This stock is set for a massive move. It's the best bargain, and super undervalued. No offering, no dilute. Outstanding Shares 2,355,249. The chart looks poised for the run. This will fly soon! It’s a matter of time Bullish.

Lymphir is the only CTCL therapy that targets the interleukin-2 (IL-2) receptor found on malignant T-cells and Tregs. This is the first indication for Lymphir and Citius Pharma’s first FDA-approved product.

Citius Pharmaceuticals (CTXR), the parent company, owns 92% of the outstanding shares of CTOR, and it also owns Mino-Lok.

Mino-Lok (For Cancer and Infection Prevention)
Successful Phase 3 Clinical Trial of Mino-Lok®. Mino-Lok® is on a pathway to a New Drug Application (NDA) submission which includes all the clinical trial data, manufacturing details, labeling information, and proposed use for the drug.

Phase 2 clinical trials. 1. CanStem 303C (Stem Cell Therapy for Cancer)
CanStem 303C is one of Citius Oncology's lead candidates. It's an investigational cell therapy aimed at treating cancer relapse and recurrence.